GlassScriptPhysician profile
Michael NP Busch
NPI 1235680331
$3,485.04
in general payments reported to CMS, 2019-2025
32 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $873 · 2023: $1,141 · 2024: $568 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.45 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $551.72 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $417.08 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $354.01 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $320.78 | 2021-2023 | Rexulti |
| Astellas Pharma US INC | $255.10 | 2022-2025 | Veozah |
| Glaxosmithkline, LLC. | $231.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $152.66 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.81 | 2021-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $91.08 | 2021 | |
| Mylan Specialty L.P. | $87.28 | 2022-2023 | Yupelri, Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $84.17 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $78.21 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $75.48 | 2021-2024 | Jardiance, Mounjaro |
| Exact Sciences Corporation | $66.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $65.87 | 2022-2024 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.86 | 2024-2025 | Invega Sustenna, Spravato |
| Organon LLC | $56.58 | 2022-2024 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $50.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.66 | 2023 | |
| Axsome Therapeutics, INC. | $43.25 | 2023 | Auvelity |
| Dexcom, INC. | $33.98 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $33.00 | 2024-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $32.88 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $30.73 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Corcept Therapeutics | $26.65 | 2025 | Korlym |
| Abbott Laboratories | $21.53 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $19.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2023 | Xifaxan |
| Lundbeck LLC | $16.09 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.43 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.89 | 2022 | |
| Hologic Sales and Service, LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.